Dear member of the investment community,
Actelion Ltd will host a Conference Call / Audiocast on the positive SERAPHIN Study Results today, on Monday, 30 April 2012, at 14.00 CET / 13.00 BST / 08.00 a.m. EST.
The company announced today that its endothelin receptor antagonist, macitentan met the primary endpoint in the pivotal Phase III outcome study in patients with pulmonary arterial hypertension.
|30 April 2012||14.00 - 15.00 hrs||Basel (CET)|
|13.00 - 14.00 hrs||UK (BST)|
|08.00 - 09.00 a.m.||US (EST)|
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.
|Dial:||Europe:||+41 (0)44 580 00 74|
|UK:||+44 (0)203 367 94 53|
|US:||+1 866 907 59 23|
Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.
Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.
The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
+41 61 565 62 62
+1 646 737 49 72